Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HII stock price vs NVAX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NVAX's multiple
Needs NVAX P/E.
Implied fair value · at HII's multiple
Needs HII P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HUNTINGTON INGALLS INDUSTRIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
NOVAVAX INC · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
GENERAL DYNAMICS CORP
HII vs GD
LOCKHEED MARTIN CORP
HII vs LMT
NORTHROP GRUMMAN CORP /DE/
HII vs NOC
TEXTRON INC
HII vs TXT
Howmet Aerospace Inc.
HII vs HWM
AXON ENTERPRISE, INC.
HII vs AXON
Moderna, Inc.
HII vs MRNA
BioNTech SE
HII vs BNTX
Emergent BioSolutions Inc.
HII vs EBS
ASTRAZENECA PLC
HII vs AZN
GSK plc
HII vs GSK
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HII can sustain its current profitability and execution without needing NVAX-level growth to justify value, then holding or accumulating on pullbacks makes more sense than using NVAX as a valuation anchor, because HII's quality metrics are solid and its discounted DCF range still sits well below the current price.
On a P/E basis, HII trades at 18.9x versus NVAX at 3.8x, while the provided P/E-implied price for HII is $58.10 versus its current $291.50, indicating an 80.1% downside to that NVAX-based benchmark. However, NVAX comparison is not clean because HII has far higher revenue and stronger balance-sheet/quality characteristics, while NVAX has much faster growth but weak profitability and negative ROIC.
Supporting Metrics
